May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Penetration of Gatifloxacin Ophthalmic Solution 0.3% into Aqueous Humor of Patients Undergoing Cataract Surgery
Author Affiliations & Notes
  • Y. Chu
    Chu Laser Eye Institute, Edina, MN
  • Footnotes
    Commercial Relationships  Y. Chu, Allergan, Inc. F.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4007. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Chu; Penetration of Gatifloxacin Ophthalmic Solution 0.3% into Aqueous Humor of Patients Undergoing Cataract Surgery . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4007.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the penetration of gatifloxacin ophthalmic solution 0.3% (ZymarTM, Allergan, Inc.) into aqueous humor of patients undergoing standard cataract surgery. Methods: This single center, open–label clinical study determined the concentration of gatifloxacin in the aqueous humor of 25 patients who underwent a dosing regimen of gatifloxacin 0.3% prior to cataract surgery. These patients instilled gatifloxacin 0.3% in the eye to receive surgery at a dosing regimen of 1 drop 4 times/day for 3 days, and then 1 drop every 15 minutes for 1.5 hours prior to surgery. Anterior chamber fluid was withdrawn during surgery, and the gatifloxacin concentration was quantified by HPLC. Data were reported for 22 samples. Results: The mean concentration of gatifloxacin in aqueous humor was 1.101 µg/mL. Conclusions: Gatifloxacin ophthalmic solution 0.3% showed good penetration into the aqueous of patients at the time of cataract surgery.

Keywords: antibiotics/antifungals/antiparasitics • bacterial disease • aqueous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×